Kindred Biosciences Inc

Kindred Biosciences — Investor Presentation (January 2020)

42 slides from Kindred Biosciences's investor presentation, Jan 13, 2020

  1. Slide 1: We are a Leader in Pet Therapeutics

    We are a Leader in Pet Therapeutics

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking sta

  3. Slide 3: Growing Spend on Pet Family Members

    Growing Spend on Pet Family Members 3 We spend We spend 35% 71% We spend We spend ...Because 95% of pet parents million $490 million of pets sleep $890 of owners would give up generously $75.4 billion on Valentine’s on Halloween pets are in bed with consider pets their cell phone a year on pets thei

  4. Slide 4: KindredBio Highlights

    KindredBio Highlights 4 Leveraging Attractive ROI One of the validated potential, only pet human drugs with cost of biopharmaceutical to maximize development companies probability of 100 times lower in the world success than human 1 2 3 markets First commercial Leading products for the Deep pipeline

  5. Slide 5: Unique Development Strategy

    Unique Development Strategy 5 Reduce technical risk Pursue Shorten molecules timelines known to work in humans KindredBio Repurposes Human Drugs Average of for Pets Reduce $5-8M to financial risk develop a drug in 3-6 years Portfolio approach

  6. Slide 6: High Willingness to Pay

    High Willingness to Pay 6 Average spend to save life of pet1 Generic Dispensing Rates2 Few generic companies & low penetration 100% $10,000 $10,200 $10,330 81% No automatic 80% $8,000 substitution at pharmacy $6,000 60% Peak sales often reached post patent $4,000 40% expiration $2,000 20% 7% No bios

  7. Slide 7: Advantages Over Human Health

    Advantages Over Human Health 7 ATTRACTIVE Market sizes are 10 times smaller than human markets, but the cost of ROI development is 100 times lower POTENTIAL Faster, less expensive development pathway Strong brand loyalty post patent expiration Portfolio approach minimizes volatility Therapeutics pai

  8. Slide 8: Industry Leading Product Pipeline

    Industry Leading Product Pipeline 8 MAJORITY OF DEEP PIPELINE MIX OF PIPELINE IS WITH > 20 PROGRAMS NEW MODALITIES AND INNOVATIVE BIOLOGICS IN DEVELOPMENT GREENFIELD MARKETS Laboratory Field MOLECULE Proposed Indication Preclinical Pilot Studies Pilot Studies Pivotal Study IL31 antibody Atopic derma

  9. Slide 9: Recent and Expected Milestones

    Recent and Expected Milestones 9 Molecule Proposed Indication 2019 2020 KIND-012 (dipyrone injection) Control of fever in horses Approval Commercial launch Mirataz® (mirtazapine Control of weight loss Approval Commercial launch transdermal ointment) EU in cats KIND-012 (dipyrone oral gel) Control of

  10. Slide 10: First Products & Commercialization

    First Products & Commercialization

  11. Slide 11: Mirataz (mirtazapine transdermal ointment)

    Mirataz® (mirtazapine transdermal ointment) 11 The FIRST and ONLY FDA-approved transdermal medication for the management of weight loss in cats Mirataz is classified pharmacologically as a weight-gain drug “ANOTHER PILL? GIVE IT TO THE DOG.“ IMPORTANT SAFETY INFORMATION: Mirataz® (mirtazapine transd

  12. Slide 12: Feline Weight Loss can be Fatal

    Feline Weight Loss can be Fatal 12 Million cats are Million cats* diagnosed with are treated for unintended unintended weight loss weight loss 9each year 3each year Topical application to the cat’s inner ear Unintended weight loss is a leading cause of feline veterinary visits is more appealing than

  13. Slide 13: Mirataz clinical results

    Mirataz® (mirtazapine transdermal ointment) clinical results 13 MIRTAZAPINE CONCENTRATIONS IN CATS AT STEADY STATE FOLLOWING DAILY DOSING (DAY 13; 0.5 MG/KG)1 Efficacy In clinical studies, Mirataz® achieved measurable and steady plasma levels of mirtazapine and effectively resulted in weight gain Mi

  14. Slide 14: Broad Uptake Thus Far

    Broad Uptake Thus Far 14 Mirataz® (mirtazapine transdermal ointment) launched in July of 2018 Approximately 51% of veterinary clinics have 51% purchased Mirataz Approximately 68% of veterinary clinics have 68% re-ordered product Figures as of 3Q 2019 quarterly results

  15. Slide 15: Mirataz EU Market Opportunity & Next Steps

    Mirataz EU Market Opportunity & Next Steps 15 NOW APPROVED! Veterinary Therapeutics Market Broad label: Mirataz is the first veterinary therapeutic for poor appetite and weight loss resulting from chronic medical conditions in the EU United States EU Other European sales may exceed the US and uptake

  16. Slide 16: Zimeta (dipyrone injection)

    Zimeta™ (dipyrone injection) 16 NOW APPROVED! Zimeta™ (dipyrone injection) is the FIRST and ONLY drug FDA approved for the control of pyrexia (fever) in horses Dipyrone, the active ingredient inZimeta , is a member of the pyrazolone class of non-steroidal anti-inflammatory drugs (NSAIDs) and has a c

  17. Slide 17: Fever Can Cause Dangerous Complications & Lost Training Days

    Fever Can Cause Dangerous Complications & Lost Training Days 17 Million horses Million are seen by horses in veterinarians the United for fever 8 States 1each year Fever is associated with many negative outcomes: Cost to commercialize equine products ૡ Dehydration significantly less than companion a

  18. Slide 18: Zimeta clinical results

    Zimeta™ (dipyrone injection) clinical results 18 Efficacy · In clinical studies, Zimeta™ demonstrated rapid and effective control of fever in horses.1,2* · In a field study, clinical signs associated with adverse events were reported in less than 2% of Zimeta treated horses.2 · This is the first-tim

  19. Slide 19: Commercialization Strategy & Team

    Commercialization Strategy & Team 19 World-class Commercial Team Commercialization Strategy Sales force has Companion animal - average experience 25 person direct field of 15+ years sales force Over 10 launches Sales forces work per team member in conjunction with on average distributors Team comes

  20. Slide 20: Focus on Biologics

    Focus on Biologics

  21. Slide 21: Biologics: The Future of Veterinary Medicine

    Biologics: The Future of Veterinary Medicine 21 VETERINARY MEDICINE TO FOLLOW HUMAN MARKET, IN WHICH TOP DRUGS ARE BIOLOGICS Industry leading biologics programs Declining manufacturing costs make biologics competitive in animal health Administered in office, so veterinarian maintains revenue stream

  22. Slide 22: State-of-the-Art Manufacturing Plants

    State-of-the-Art Manufacturing Plants 22 Burlingame, CA Elwood, KS One of the Plant to Construction facility fully facility includes only biologics manage COGS to support commissioned. approx. manufacturing with direct Elwood initial Manufactures 2 180,000 ft facilities in ability to production feli

  23. Slide 23: Half-Life Extension

    Half-Life Extension 23 ●● Normal canine antibodies have half-life of 9-12 days ●● KindredBio has developed technology to modify the Fc tail of antibodies to increase half-life to 3X normal ●● This means KindredBio antibodies could be administered every 3 months and/or could lower cost of goods by 3X

  24. Slide 24: Deep Pipeline

    Deep Pipeline

  25. Slide 25: Canine Dermatitis - Large and Growing Market

    Canine Dermatitis - Large and Growing Market 25 Prevalence Diagnosis #1 10-15% Itch is #1 have atopic reason for canine dermatitis, veterinarian an allergic visits skin disease Two recent drugs Growing Market Key Profit Center are selling over 47% 83% increase in of dogs seen by $700M itchy dog derm

  26. Slide 26: Need for New Biologicals

    Need for New Biologicals 26 Not all products work for every patient Treatment non-response rates 70% 80% as high as one in four patients, depending on allergy GP veterinarians Dermatologists desire a new biological desire a new treatment option for biological treatment Treating pruritis is multimoda

  27. Slide 27: Canine Dermatitis Pipeline

    Canine Dermatitis Pipeline 27 IL4R and Other IL4/IL31 SINK Candidates IL4/IL13 SINK blocks inflammation Positive results from pilot study of IL4R. Evidence of positive efficacy and dose Analogus to dupilumab - which was respose recently approved in human atopic dermatitis Inital pilot study of IL17

  28. Slide 28: Canine Parvovirus

    Canine Parvovirus 28 Highly Contagious Disease Affects mostly puppies, with no approved therapies Disease Burden Mortality rate as high as 91% Cost Burden Supportive care can cost thousands General practitioners, emergency hospitals, and shelters Market Opportunity More than 60% of shelter dogs lack

  29. Slide 29: Canine Inflammatory Bowel Disease

    Canine Inflammatory Bowel Disease 29 Majority of cases involve chronic states of diarrhea, vomiting, gastroenteritis, and other symptoms Prevalence Diarrhea prevalence >5% Chronic condition, with diagnosis common in middle age Disease Burden Existing treatments can have significant drawbacks, leadin

  30. Slide 30: Non-regenerative Anemia in Cats

    Non-regenerative Anemia in Cats 30 POSITIVE RESULTS FROM Chronic condition est. to afflict millions of PILOT EFFECTIVENESS STUDY older cats, with no approved treatments OF FELINE RECOMBINANT ERYTHROPOIETIN About 50% of older cats develop chronic Statistically significant improvement in kidney diseas

  31. Slide 31: Non-regenerative Anemia in Cats Pilot Results

    Non-regenerative Anemia in Cats 31 Pilot Results* Treatment success was defined as: HCT returning to the laboratory normal Least Squares (LS) Means of Hematocrit over Time reference range by Week 6 35 P < 0.0001 P < 0.0001 ) n=19 P < 0.0001 E n=20 n=19 OR 95.5% S 100 ( 30 P < 0.0001 Success ) n=22 P

  32. Slide 32: Equine Gastric Ulcer Syndrome

    Equine Gastric Ulcer Syndrome 32 90% Affects all types of horses 74% of racing horses develop ulcers Clinical symptoms: poor appetite, loose stools, poor >60% condition, low performance and behavioral issues of sport horses develop ulcers Pivotal study 50% commenced of recreational horses develop ul

  33. Slide 33: Sepsis in Foals Pilot Results

    Sepsis in Foals 33 Pilot Results* TNF Antibody in Equine Sepsis Statistically significant mortality benefit. Combined analysis of 19 foals enrolled in two studies. *Data has not been evaluated by the FDA

  34. Slide 34: Corporate Information

    Corporate Information

  35. Slide 35: Levers Driving Growth

    Levers Driving Growth 35 Biologics facilities provide potential for contract Multiple potential Deep pipeline manufacturing blockbuster launches by 2022 beginning to Assessing partnership launch opportunities for pipeline candidates Targeting Focus on highest non-dilutive value capital investments s

  36. Slide 36: Select Summary Financials

    Select Summary Financials 36 September 30, 2019 Quarter Year-to-Date Net product revenues $1.1 $2.9 Capital Operating costs and expenses Cost of Product Revenues $0.1 $0.4 Structure & Research and Development $7.3 $21.2 Market Cap1 Selling, General and Administrative $9.4 $28.3 Analyst Total cash op

  37. Slide 37: Compelling Value Proposition

    Compelling Value Proposition 37 Significant Progress to Date Valuable Pipeline in Place Outlook is Bright Reduce Reduce Reduce • First threetechnical approvals risk • Deep pipelinetechnical of risk>20 • Growing technicalrevenues risk validate business model product candidates - from three commercial

  38. Slide 38: Contact

    Contact Investor Relations 38 For investor inquiries: Katja Buhrer [email protected] (917) 969-3438 Corporate Office: San Diego Office: 1555 Bayshore Hwy, Suite 200 591 Camino De La Reina, Ste 407 Burlingame, CA 94010 San Diego, CA 92108 Tel (650) 701-7901 © 2020 Kindred Biosciences, Inc,

  39. Slide 39: Mirataz - Prescribing Information

    Mirataz - Prescribing Information 39

  40. Slide 40: Mirataz - Prescribing Information

    Mirataz - Prescribing Information 40

  41. Slide 41: Zimeta - Prescribing Information

    Zimeta - Prescribing Information 41 65000010 - AW v.1 ref.: D300.060 F57 Zimeta™ Control (dipyrone injection) Product Adverse Reaction (N=107) (N=31) Elevated Serum Sorbitol Dehydrogenase (SDH) 5 (5%) 5 (16%) Hypoalbuminemia 3 (3%) 1 (3%) Gastric Ulcers 2 (2%) 0 (0%) Hyperemic Mucosa Right Dorsal Co

  42. Slide 42: Zimeta - Prescribing Information

    Zimeta - Prescribing Information 42 65000010 - AW v1 ref.: D300.060 F57  PLEASE TEAR ALONG PERFORATIONS 

Kindred Biosciences — Investor Presentation (January 2020) on 6ix